PTO/SB/08A (Modified)

Substitute for form 1449A/PTO					Complete if Known									
INI	EO	RMATION	DI.	8CI 0	CUDE		Parent Ap	pln	Number	-09/	295,303	0/679	1,429	
4		EMENT B		_			Divisional Filing Date			October 7, 2003			<i>†</i>	
-						i	First Named Inventor			HOSMANE, et al.				
(use a	(use as many sheets as necessary)							Un	it .	16				
Date 7	This I	Paper Filed: O)cto	ber 7, 20	03	:	Parent Exa	ami	iner Name	Kh	are, D.			
Sheet	1		of	1	-		Attorney D	oc	ket Number	464	81			
IIS B	ATEN	IT DOCUMENTS	<u> </u>	·										
Examin	Cite	U.S. Patent D		nent	Name of P	atente	e of Applicant	T 6	Date of Publication	of T	Pages Colum	ns Lines V	Vhere	
er Initials*	No.		Kind	Code ^w			cument		Cited Document MM-DD-YYYY	nt Relevan		evant Relevant Fi	vant elevant Figures	
M	AR	5 521 161		111	Mallev et :	al		М	lav 28 1996	工				
	RR			ļ				ļ						
	CR DR			-		<u>.</u>		┝						
Examin	Cite	ATENT DOCUMI	ENT	Documen	ıt	C	ountry		Date of Publication	ent	English Translation Abstract Readily Available			
Initials*	<u> </u>	Name		Number					MM-DD-YYY	Υ	End No	Encl.	No	
	FR		+					\dashv				<u> </u>		
_	FR GR		-		 			┪				 		
OTHER		uding in this orde												
- J.VV \	HR.	Omura et al. "Ade Isolation And Prop							ntaining Chionne	Pron	uclion.			
	IR	Nakamura et al "S	Sythe	sis Of Cofo	rmycin"./ A	m Ct	em Soc 197	74	96 4326-4327					
<u></u>	.iR	Won et al " A Nov						_						
	KR	Showalter et al "A												
	I NH	8-Tetrahydro-3-12				_								
		Homologues of Pe						1			*			
	IR	Anarwal et al "Co	form	voin and De	Oxycoformy	cin: Ti	aht-hindina Ir	nhih	nitors of Adenosi	ne " in	-0			
ļ	ļ	"Chemistry and Ri	inlanı	v of Wilclens	ides and Ni	iclenti	des "R F H	am	non R K Robin	s				
<u> </u>	├	and R Townson									·			
	MR	Smyth at al Dam						nd	l vmnhomas" A	nnals	of the			
 	ME	New York Acaden							4	4000	44.456.155			
	HAH	Klohs W. D. Krak	<u>er A</u> I	LIPENTOS LIOT	tatin future		4 .	aco X	Nogical Reviews	1992 //` /	Lean			
	· · · · ·			<u> </u>					11/1 / //	<u> </u>	<u> </u>			
Examine Signatur		N	W	NI.			Date Considered	j	11610	05				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (Modified)

Substitute	e for fo	m 1449AVP10				Complete if Known						
18.0			DI	5CI O	CLIDE	Parent App	oln Number	.09/2	295,303			
		RMATION EMENT B				Divisional I	Filing Date	October 7, 2003 HOSMANE, et al.				
٠.	<i>,</i>		,		·	First Name	d Inventor					
(use as	man	y sheets as ne	cessa	ary)		Group Art	Unit	162	.3	ŧ		
Date This Paper Filed: October 7, 2003						Parent Exa	miner Name	Kha	are, D.			
Sheet	1		of	2		Attorney D	ocket Number	464	81			
							Ţ					
J.S. PA	ATEN	T DOCUMENT	<u> </u>		i i			— т				
Examin	Cite	U.S. Patent Document			Name of Patente of Cited Do		Date of Publication Cited Document		Pages, Column		iere	
er nitials*	No.	Kind Code ^w Number (if known)		Us Cited Di	JCOMENT	MM-DD-YYYY	Relevant Passages or Relevant Figures Appear			res		
	AS						-					
	BS				<u> </u>							
Examin er Initials*	Cite No.	Inventor Name		Documer Number	nt C	Country	Cited Docum MM-DD-YY		Abstract Encl No	Readily Available Encl.) No	
	CS.											
THER	DS ES ES ES HS	Hosmane et al. nucleotides and It Aldiazenine It Hosmane et al. "fat" Guanine Iff system Heteroco Hosmane et al." evnanded nucle system imidazo Hosmane et al. vanthine (fr). "fa	The Sy Home Ora (Models S) and ycles 1 (CAPI osides (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (CAPI (onthesis and chem 1990 for "Fat" N "Fat" Hyno 986 Vol 24 US 113:212 nucleofide II 41diazen IIS 107:772 nine (fot Ar (1986) 24(I Bionhysical Invocantaining the 5-7 Vol. 55 5882-5 ucleosides and N yanthine (fHx) Al 2743-2748 2564) "The synth s and hamonoly ine "A Ora Chei rad "fat" hypoyanti 10) 2743-8	estigating of No. Leged Heleronics Lucientides Lucientides	e, Pertinent Paravel Ring-Expander wells Ring Expander wells of "Fat" X2 and Investigation the 5-7-fused helps and nucleotide ones of the imidazon of two isomeric rings.	anthine A) Diaz ns of or elerocycles Synti	eosides. (fX) enine ovel ring- olic ring- hesis of "fat" (1 4) diazenine		,	
	ıs	165/1) 106-13 Schneller et al. (nucleosides and their 5-mono, and diphosphate derivatives * Rinchem Rinnhys Res Commun (1989) 165(1) 196-13 Schneller et al. (CAPLUS 101-230220) *Synthesis and biological evaluation of 6-amino-1H-ovrollol(3.2-c) pridin-4(5H)-one(3.7-dideazaguanine)) * J. Med Chem. (1984), 27(12), 1737-9									
	العال	<u> </u>				. 0					<u> </u>	
C			X	MIT	resident	d'P	ont is m	ru	sen.		 	
:	KS	I										
Examine		dl	me	rl		Date Considered	1 1/6/	05	-			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO	Complete if Known							
INFORMATION DISCLOSURE	Parent Appln Number	-09/295,303 10/679, 429 October 7, 2003						
STATEMENT BY APPLICANT	Divisional Filing Date							
	First Named Inventor	HOSMANE, et al.						
(use as many sheets as necessary)	Group Art Unit	16						
Date This Paper Filed: October 7, 2003	Parent Examiner Name	Khare, D.						
Sheet 1 of 1	Attorney Docket Number	46481						

U.S. P.	ATEN	NT DOCUMENTS					
Examin er Initials*	Cite No.	U.S. Patent Document	Name of Patentee of Applicant	Date of Publication of	Pages, Columns, Lines, Where		
		Kind Code ^w Number (if known)	of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear		
M	AR	5 521 161	Mallev et al	May 28 1996			
	BR	-					
	CR						
L	DR_		<u></u>				

FOREIGN PATENT DOCUMENTS

Examin er Initials*	Cite No.	Inventor Name	Document Number	Country	Date of Publication of Cited Document MM-DD-YYYY	English Abstract Encl No	Translation Readily Available Encl. No
	FR	141					
	FR						
	GR						

OTHER (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages

M	HR	Omura et al. "Adechlorin, A New Adenosine Deaminase Inhibitor Containing Chlorine Production.	
		Isolation And Properties" Journal of Antibiotics 1985, 38, 1008-1015	
	IR	Nakamura et al. "Sythesis Of Coformycin", I. Am. Chem. Soc. 1974. 96. 4326-4327	
	JR	Won et al. " A Novel Adenosine and Ara-A Deaminase Inhibitor (R)A-12-Denovy- D	
		erythronentofuranosyl)-3 6 7 8-tetrahydroimidazold 5-didiazeetin-8-ol * .I. Heterocycl. Chem. 1974, 11	
	KR	Showalter et al "Adenosine Deaminase Inhihitors Synthesis and hintonical Evaluation of (+/-)-3 6 7	
		R-Tetrahydro-3-12-hydroxyethoxy/methyllimidazol4 5-d1[1 3]diazenin-8-ol and Some Selected C-5	
		Homologues of Pentostatio", I Med Chega 1983, 26, 1478-1482	
L	IR	Anarwal et al. "Coformycin and Denvycoformycin: Tight-hinding Inhibitors of Adenosine " in	
		"Chemistry and Rinlany of Mucleasides and Nucleatides " R. F. Harmon, R. K. Rohins	
		and I. R. Townsepat Ed - Academic Press, New York, 1978: no. 159-197	
	MR	Smyth et al Denyycoformycin in The Treatment Of Leukemias And Lymnhomas" Annals of the	
		New York Academy of Sciences 1985 451 123-128	
	MR	Klohs W. D.: Kraker, A. J. "Pentostatin: future directions". Pharmacological Reviews 1992, 44, 459-477	
سن		NOT considered: bout is not clear.	

Examiner Signature	dillare.	Date Considered	16105

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A	(Modified
1 10/00/00/1	uwoamea

							PTO/SB/08A (Modified)							
Substitut	e tor t	form 1449A/PTO					Complete if Known							
INI	EΛ	RMATION	וח	פרו ה	SIIDE		Parent App	oln N	lumber	09/295,303				
		RIVIATION				Ī	Divisional (Filing	Date	Oct	ober 7,	200	3	-
					J. 1111		First Name	d In	ventor	HOSMANE, et al.				
(use as	(use as many sheets as necessary)						Group Art	Unit	-	162		· ·		
Date T	his	Paper Filed : (Octo	ber 7, 20	03	f	Parent Exa	min	er Name		are, D.			
Sheet	T_1		of	2		\dashv	Attorney D	ocke	et Number	464				
-										404				
U.S. P	ATE	NT DOCUMENT	s											
Examin	Cite	U.S. Patent	Docun	nent	Name of Pate				te of Publication	of	Pages, C		s, Lines, Whe	ere
er Initials*	No.	Number		Code ^w nown)	of Cited	90 DOC	ument		Cited Document MM-DD-YYYY	Passages or		s or R	elevant Relevant Figures ppear	
	AS													
	BS	<u> </u>		<u></u>										
Examin er	Cite	ATENT DOCUM	IENT	Documer	it .	Coi	Date of Publication			ent Abstract		Translatio Readily	n	
Initials*		Name		Number			MM-DD-YY		MM-DD-YYY	YY End No		No	Available Encl.	No
	cs													
OTHER (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages DS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigatins of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Investigations of Novel Ring-Expanded Nucleosides. DIS Hosmane et al. The Synthesis and Biophysical Inve														
	ES	Hosmane et al. (6	CAPLI	US 113-212	5641 "The sy									
		system imidazof						U TOP	a'/-nised net	PLUCAL	enc rinn-			
	GS.	Hosmane et al. ((CAPLI	IS 107-777	FAI "Mondole I	for "fa	il" nucleoside							
		gygtem " Heteron				<u></u>		-CISCO	, ин липаим	- 11-311	, At DISTAL			
	HS	Hosmane et al ((+	
		165/1\ 106-13			- cumponnat	ite (JD)	NAMES AND	<u> </u>	n Minings RA			AST.		
	ıs	Schooller et al (APLI	IS 101:230	220) "Synthe	sis ar	nd biological	evalı	uation of 6-ami	ino-1H	-nvrolloll3	2-c1		
-		ofridin-4/5H)-nne/3 7-dideazaguanine)) * 1 Med Chem /1984) 27/12) 1737-9												
F	.IS	1	7	MTC	overte	m	1 . Px	nw.F	- is not	d	sen.		1	
	KS				V. 1. V. 1.									
Examine Signature		d/N	nn	pl			Date Considered		1/6/0	15				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.